Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ 42)
accompanied by brain atrophy and cognitive decline. Several recent studies have shown …

Objective: Several models have been proposed for the evolution of Alzheimer's disease
(AD) biomarkers. The aim of this study was to identify changepoints in a range of biomarkers …

Neurofibrillary tangles (NFT) and amyloid plaques are hallmark neuropathological features
of Alzheimer's disease (AD). There is some debate as to which neuropathological feature …

Introduction Brain structural changes in preclinical Alzheimer's disease (AD) are poorly
understood. Methods We compared the changes in cortical thickness in the ADNI cohort …

Previously it was reported that Alzheimer's disease (AD) patients have reduced amyloid
(Aß1-42) and elevated total tau (t-tau) and phosphorylated tau (p-tau181p) in the cerebro …

Brain atrophy and altered CSF levels of amyloid β (Aβ42) and the microtubule-associated
protein tau are potent biomarkers of Alzheimer's disease (AD)-related pathology. However …

There is evidence of longitudinal atrophy in posterior brain areas in early-onset Alzheimer's
disease (EOAD; aged< 65 years), but no studies have been conducted in an EOAD cohort …

Identifying dynamic changes in biomarkers and clinical profiles is essential for
understanding the progression of Alzheimer's disease (AD). The relevant studies have …

BACKGROUND: Low amyloid β42 (Aβ42) and high total tau and phosphorylated tau (p-tau)
concentrations in the cerebrospinal fluid (CSF) are biomarkers of Alzheimer's disease (AD) …

Objective To determine the ordering of changes in Alzheimer disease (AD) biomarkers
among cognitively normal individuals. Methods Cross-sectional data, including CSF …